Regulatory Scrutiny And High Costs Will Hinder Gene Therapy Progress

Published
09 Apr 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$347.89
12.1% overvalued intrinsic discount
16 Aug
US$389.88
Loading
1Y
-20.1%
7D
4.1%

Author's Valuation

US$347.9

12.1% overvalued intrinsic discount

AnalystLowTarget Fair Value

Shared on07 May 25
Fair value Decreased 20%

Shared on30 Apr 25
Fair value Increased 0.39%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Increased 0.42%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Increased 19%

AnalystLowTarget made no meaningful changes to valuation assumptions.